Mistelihoidon näyttö kliinisissä tutkimuksissa
Positiivinen yhteisvaikutus (synergia) muiden onkologisten hoitojen kanssa
Wode, K., Kienle, G. S., Björ, O., Fransson, P., Sharp, L., Elander, N. O., Bernhardson, B.-M., Johansson, B., Ardnor, C. E., Scheibling, U., Nordberg, J. H., & Henriksson, R. (2024). Mistletoe Extract in Patients With Advanced Pancreatic Cancer. Dtsch Arztebl International, 121(11), 347-354. https://www.aerzteblatt.de/int/article.asp?id=239558
Shin, J., Yim, E., & Kang, C. M. (2023). Viscum album, as alternative and bridge to palliative chemotherapy in recurrent gallbladder cancer following laparoscopic radical cholecystectomy: a case report. Korean J Clin Oncol, 19(2), 88-92. https://doi.org/10.14216/kjco.23016
Thronicke A, Reinhold T, von Trott P, Grah C, Matthes B, Matthes H & Schad F. Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients. Plos ONE. 2020;15(7):e0236426. Published 2020 Jul 27. doi: 10.1371/journal.pone.0236426
Thronicke A, Reinhold T, von Trott P, Matthes H & Schad F. Cost-Effectiveness of Real-World Administration of Concomitant Viscum album L. Therapy for the Treatment of Stage IV Pancreatic Cancer. Evid Based Complement Alternat Med. 2020;2020:3543568. Published 2020 Mar 12. doi: 10.1155/2020/3543568
Weissenstein U, Kunz M, Oufir M, Wang J T, Hamburger M, Urech K, Regueiro U and Baumgartner S. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro. BMC Complement Altern Med, 2019;19:23. DOI: 10.1186/s12906-019-2439-2
Thronicke A, Oei S L, Merkle A, H M and Schad F. Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients. Medicines (Basel), 2018;5:100. DOI: 10.3390/medicines5030100
Thronicke A, Oei SL, Grah C, Matthes B and Schad F. Nivolumab-induced toxicity profile in patients with advanced or metastasized lung cancer treated with Viscum album L. extracts. In Proceedings of the German Cancer Congress, DKK2018, 2018.
Schad F, Thronicke A, Steele ML, Merkle A, Matthes B, Grah C and Matthes H. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One, 2018;13:e0203058. DOI: 10.1371/journal.pone.0203058
Schad F, Axtner J, Kroz M, Matthes H and Steele ML. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations. Integr Cancer Ther, 2018;17:41-51. DOI: 10.1177/1534735416681641
Weissenstein U, Kunz M, Urech K, Regueiro U and Baumgartner S. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Complement Altern Med, 2016;16:271. DOI: 10.1186/s12906-016-1246-2
Tröger W, Zdrale Z and Stankovic N. Fünf-Jahres-Nachbeobachtung von Patientinnen mit Brustkrebs nach einer randomisierten Studie mit Viscum album (L.) Extrakt. Deutsche Zeitschrift für Onkologie, 2016;48:105-110. DOI: 10.1055/s-0042-113505
Evans M, Bryant S, Huntley AL and Feder G. Cancer patients' experiences of using mistletoe (Viscum album): a qualitative systematic review and synthesis. The Journal of Alternative and Complementary Medicine (New York, N.Y.) 2016;22(2):134–144.
Weissenstein U, Kunz M, Urech K and Baumgartner S. Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complementary and Alternative Medicine, 2014;14:01. Sep. DOI: 10.1186/1472-6882-14-6
Tröger W, Zdrale Z, Tisma N and Matijasevic M. Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial. Evidence-Based Complementary and Alternative Medicine, 2014;2014:01. Sep. DOI: 10.1155/2014/430518
Bar-Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E and Haim N. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer, 2013;49:1058-1064 DOI: 10.1016/j.ejca.2012.11.007.
Tröger W, Zdrale Z, Stankovic N and Matijasevic M. Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with viscum album (L.) extract to chemotherapy alone. Breast Cancer (Auckl), 2012;6:173-180. DOI: 10.4137/BCBCR.S10558
Matthes H, Friedel WE, Bock PR and Zänker KS. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med, 2010;10:430-439. DOI: 10.2174/156652410791317057
Kienle GS and Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther, 2010;9:142-157. DOI: 10.1177/1534735410369673
Tröger W, Jezdic S, Zdrale Z, Tisma N, Hamre HJ and Matijasevic M. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer, 2009;16:35-45
Friedel WE, Matthes H, Bock PR and Zänker KS. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol 2009;7:137-145
Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J and Lin HS. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res, 2004;24:303-309.
Bock PR, Friedel WE, Hanisch J, Karasmann M and Schneider B. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland]. Arzneimittelforschung, 2004;54:456-466. DOI: 10.1055/s-0031-1296999